Suraksha Diagnostic IPO: 10 key points you need to know ahead of ₹846 crore public offer opening

Suraksha Diagnostic IPO: Integrated diagnostic chain Suraksha Diagnostic's ₹846.25 crore initial public offering will open for subscription on Friday, November 29. The company's equity shares will likely be listed on the NSE and the BSE on December 6.

Suraksha Diagnostic IPO: 10 key things to know

• Suraksha Diagnostic IPO subscription period: The initial share sale will be live for public subscription from November 29 to December 3.
• IPO offer structure: It is completely an offer-for-sale (OFS) worth ₹846.25 crore from selling shareholders.
• Suraksha Diagnostic IPO price band: The price range has been fixed at ₹420 to ₹441 per share. At the upper price band, the market capitalisation of the company stands at around ₹2,300 crore.
• Reservation: Half of the issue size has been set aside for qualified institutional buyers (QIBs), 35% for retail individual investors (RIIs) and 10% for non-institutional investors (NIIs).
• Issue type: Book built issue IPO
• Suraksha Diagnostic IPO lot size: An interested investor can bid for at least one lot worth ₹14,994, consisting of 34 shares.
• Objective: Since no fresh issue component exists, the company will not get any IPO proceeds.
• Book-running lead manager and registrar: ICICI Securities, SBI Capital Markets Ltd, and Nuvama Wealth Management are the public offer's book-running lead managers, while Kfin Technologies is the registrar.
• Allotment date: The basis of allotment is expected to be finalised on Wednesday, December 4.
• Listing date: The listing on the National Stock Exchange (NSE) and the BSE is scheduled for Friday, December 6.

Suraksha Diagnostic provides its customers with a one-stop integrated solution for radiology and pathology testing and medical consultation via its extensive operational network. As of March 31, 2024, it comprises a flagship central reference laboratory, eight satellite laboratories, and 194 customer touchpoints.

Suraksha offers more than 2,300 tests in Bihar, Assam, West Bengal, and Meghalaya. In the financial year 2023-24 (FY24), it conducted about 5.98 million tests and served around 1.14 million patients.